var data={"title":"Arginine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Arginine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5665?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=arginine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Arginine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=arginine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Arginine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136608\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>R-Gene 10</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136622\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136609\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnostic aid (pituitary function): Note:</b> Dosing based on arginine hydrochloride product. IV: 30 g as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperammonemia, acute (urea cycle disorders) (off-label use): Note: </b>\n      <b>Dosing based on arginine hydrochloride product </b>and on specific enzyme deficiency. Therapy should continue until ammonia levels are in normal range. If a loading dose is used, it should not be repeated. Arginine dose may be adjusted downward if patient becomes hypotensive and/or when the exact enzyme deficiency is identified. Administer concomitantly with sodium benzoate and sodium phenylacetate along with dialysis (NORD 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Weight-directed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Argininosuccinate synthetase (ASS, <i>Citrullinemia</i>) or </i>\n      <i>Argininosuccinate lyase (ASL)</i> <i>deficiency: </i>IV: Loading dose: 600 <b>mg/kg</b> followed by a continuous IV infusion of 600 <b>mg/kg</b>/day (NORD 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC) or N-acetylglutamate synthetase (NAGS) deficiency:</i> IV: Loading dose: 200 <b>mg/kg</b> followed by a continuous IV infusion of 200 <b>mg/kg</b>/day (NORD 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Unconfirmed/pending diagnosis:</i> IV: Loading dose: 600 <b>mg/kg</b> followed by a continuous IV infusion of 600 <b>mg/kg</b>/day (NORD 2012); if ASS and ASL are excluded as diagnostic possibilities, reduce dose to 200 <b>mg/kg</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BSA-directed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Argininosuccinate synthetase (ASS, <i>Citrullinemia</i>) or </i>\n      <i>Argininosuccinate lyase (ASL)</i> <i>deficiency: </i>IV: Loading dose: 12 <b>g</b>/<b>m<sup>2</sup></b> followed by a continuous IV infusion of 12 <b>g</b>/<b>m<sup>2</sup></b>/day (Ah Mew 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Carbamyl phosphate synthetase (CPS) or ornithine transcarbamylase (OTC) deficiency: </i>IV: Loading dose: 4 <b>g</b>/<b>m<sup>2</sup></b> followed by a continuous IV infusion of 4 <b>g</b>/<b>m<sup>2</sup></b>/day (Ah Mew 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urea cycle disorders, chronic therapy (off-label use):</b> Oral: <b>Note: Dosing based on arginine free base powder product:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Argininosuccinate synthetase (ASS, Citrullinemia) or </i>\n      <i>Argininosuccinate lyase (ASL)</i> <i>deficiency: </i>0.4 to 0.7 <b>g/kg/</b>day or 8.8 to 15.4 <b>g/m<sup>2</sup></b>/day in 3 to 4 divided doses (Nagamani 2012; NORD 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Carbamyl phosphate synthetase (CPS) or ornithine transcarbamylase (OTC) deficiency:</i> 2.5 to 6 <b>g/m<sup>2</sup></b>/day in 3 or 4 divided doses (maximum: 6 g/day) has been recommended however, citrulline may be preferred therapy (H&auml;berle 2012; NORD 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136617\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=arginine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Arginine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnostic aid (pituitary function): Note:</b> Dosing based on arginine hydrochloride product.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents &lt;60 kg: IV: 0.5 g/kg as a single dose; (maximum dose: 30 g/dose)</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Children and Adolescents &ge;60 kg: Refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hyperammonemia, acute (urea cycle disorders) (off-label use):</b> Limited data available: Infants, Children, and Adolescents:<b> Note: </b>Administered concomitantly with sodium benzoate and sodium phenylacetate. Dosage based on specific enzyme deficiency; therapy should continue until ammonia levels are in normal range. If patient already receiving arginine therapy, consider either a reduction in the loading dose or possible elimination (Batshaw 2001); if a loading dose is used, it should not be repeated (NORD 2012). <b>Dosing based on arginine hydrochloride product. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Weight-directed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS, citrullinemia) deficiency:</i> IV: Loading dose: 600 mg/kg followed by a continuous IV infusion of 600 mg/kg/day (Batshaw 2001; NORD 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC) or N-acetylglutamate synthetase (NAGS) deficiency:</i> IV: Loading dose: 200 mg/kg followed by a continuous IV infusion of 200 mg/kg/day (Batshaw 2001; NORD 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Unconfirmed/pending diagnosis:</i> IV: Loading dose: 600 mg/kg followed by a continuous IV infusion of 600 mg/kg/day (NORD 2012). If ASS and ASL are excluded as diagnostic possibilities, reduce dose to 200 mg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BSA-directed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS, citrullinemia) deficiency:</i> IV: Loading dose: 12 g/<b>m<sup>2</sup></b> followed by a continuous IV infusion of 12 g/<b>m<sup>2</sup></b>/day (Batshaw 2001; Brusilow 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Carbamyl phosphate synthetase (CPS) or ornithine transcarbamylase (OTC) deficiency:</i> IV: Loading dose: 4 g/<b>m<sup>2</sup></b> followed by a continuous IV infusion of 4 g/<b>m<sup>2</sup></b>/day (Batshaw 2001; Brusilow 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Urea cycle disorders, chronic therapy (off-label use):</b> Limited data available: Infants, Children, and Adolescents: <b>Note:</b> Dose should be individualized based on patient response; doses may need to be increased by ~50% as part of a sick-day routine (Berry 2001). <b>Dosing based on arginine free base powder product:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Weight-directed dosing: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS, citrullinemia) deficiency:</i> Oral: 400 to 700 mg/kg/day in 3 to 4 divided doses (Batshaw 2001; Berry 2001; Brusilow 1996; NORD 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC) or N-acetylglutamate synthetase (NAGS) deficiency:</i> <b>Note:</b> Citrulline may be preferred for some patients: Oral: 170 mg/kg/day in 3 to 4 divided doses  (Batshaw, 2001; Brusilow 1996; NORD 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BSA-directed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Argininosuccinic acid lyase (ASL) or argininosuccinic acid synthetase (ASS, citrullinemia) deficiency:</i> Oral: 8.8 to 15.4 g/<b>m<sup>2</sup></b>/day in 3 to 4 divided doses (Batshaw 2001; Berry 2001; Brusilow 1996; NORD 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC) or N-acetylglutamate synthetase (NAGS) deficiency:</i> <b>Note:</b> Citrulline may be preferred for some patients: Oral: 3.8 g/<b>m<sup>2</sup></b>/day in 3 to 4 divided doses (Batshaw, 2001; Brusilow 1996; NORD 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136610\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29032178\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29032179\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136592\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">R-Gene 10: 10% (300 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136578\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27747245\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">R-Gene 10 contains chloride 47.5 mEq per 100 mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136594\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer undiluted over 30 minutes. For doses &lt;30 g (&lt;300 mL), the manufacturer recommends transferring the dose to a separate container prior to administration. Prolongation of the infusion period may diminish the stimulus to the pituitary and nullify the test. In the treatment of hyperammonemia associated with urea cycle disorders (off-label use), administer loading dose over 90 to 120 minutes (NORD 2012; Ah Mew 2017); maintenance infusion should not exceed 150 mg/kg/hour (Ah Mew 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Irritant with vesicant-like properties; ensure proper catheter placement prior to and during infusion; avoid extravasation. Some recommend infusion through central access only (Ah Mew 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (if indicated); remove needle/cannula; elevate extremity. Apply dry cold compresses (Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hyaluronidase:</i> Intradermal: Inject a total of 1 to 1.7 mL (15 units/mL) as five separate 0.2 to 0.3 mL injections to border of extravasation area (Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral, powder: Arginine free base: Take with meals and space doses evenly throughout the day. Oral products available in the US are often marketed as dietary supplements. When using these products, patients should take care to ensure that they are receiving pharmaceutical grade supplements of L-arginine and verify the formulation (free base vs arginine HCl). The National Urea Cycle Disorders Foundation cautions against using oral dietary supplements of arginine HCl (National Urea Cycles Disorder Foundation).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136593\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diagnostic aid:</b> As an intravenous (IV) stimulant to the pituitary for the release of human growth hormone (hGH) in patients in whom the measurement of pituitary reserve for hGH can be of diagnostic usefulness. Used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism, and problems of growth and stature.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45090537\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Hyperammonemia (acute) associated with urea cycle disorders; Urea cycle disorders (chronic therapy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7905819\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Food and Drug Administration (FDA) has identified several cases of fatal arginine overdose in children and has recommended that healthcare professionals always recheck dosing calculations prior to administration of arginine. Doses used in children should not exceed usual adult doses.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136585\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing (with rapid IV infusion), venous irritation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache, numbness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Anaphylaxis, burning sensation of skin (due to extravasation), cerebral edema, hematuria, hyperkalemia, hypersensitivity reaction, injection site reaction, lethargy, loss of consciousness, oral paresthesia, skin necrosis (due to extravasation)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136597\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to arginine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136582\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Irritant with vesicant-like properties. Due to the hypertonicity of the IV solution, administer via IV infusion only with a patent catheter placed within a patent vein. Extravasation has resulted in burn-like reactions and skin necrosis requiring surgical intervention. Excessive rates of infusion (eg, &lt;30 minutes) may result in local irritation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Severe reactions, including anaphylaxis, have been reported; if hypersensitivity occurs, discontinue and institute supportive treatment measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion-related reactions: Excessive rates of infusion (eg, &lt;30 minutes) may result in flushing, nausea, or vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Use with caution in patients with electrolyte imbalance due to chloride content of product.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Arginine metabolism results in excretion of nitrogen-containing products. Use with caution in patients with renal impairment; decreased excretion may result in an increased amino acid or nitrogen burden.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Fatal overdose of arginine in pediatric patients has been reported. Exercise extreme caution when infusing arginine. Overdosage of arginine in children can also result in hyperchloremic metabolic acidosis or cerebral edema.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298769\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136586\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8883&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136600\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects were not observed in animal studies; however, the manufacturer does not recommend use of arginine during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136601\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Amino acids are present in breast milk, the amount following arginine administration is not known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2572943\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Acid-base status (arterial or capillary blood gases), serum electrolytes (sodium, potassium, chloride, bicarbonate, phosphorous), BUN, glucose, plasma amino acids, ammonia, blood pressure (patients with hyperammonemia associated with urea cycle disorders [off-label use]). Monitor infusion site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136581\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates pituitary release of growth hormone and prolactin through origins in the hypothalamus; patients with impaired pituitary function have lower or no increase in plasma concentrations of growth hormone after administration of arginine. In patients with urea cycle disorders, the formation of arginine is prohibited; therefore, exogenous administration of arginine is required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136596\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~33 L/kg following a 30 g IV dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively metabolized in the liver and intestines (Cynober 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: ~68% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life, elimination: 42 &plusmn; 2 minutes following a 30 g IV dose; exhibits nonlinear, dose-dependent elimination (Tangphao 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: ~2 hours; IV: 22 to 30 minutes (Bode-Boger 1998; Tangphao 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (16% during the first 90 minutes; biphasic elimination) (Tangphao 1999)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322999\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (R-Gene 10 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (300 mL): $44.68</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038532\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Arginina (PL);</li>\n      <li>Rocmaline (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20301396\"></a>Ah Mew N, Simpson KL, Gropman AL, Lanpher BC, Chapman KA, Summar ML. Urea cycle disorders overview. In: Adam MP, Ardinger HH, Pagon RA, et al editors. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2017. <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK1217/\" target=\"_blank\">http://www.ncbi.nlm.nih.gov/books/NBK1217/</a>. Published April 29, 2003. Updated June 22, 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-drug-information/abstract-text/20301396/pubmed\" target=\"_blank\" id=\"20301396\">20301396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11148549\"></a>Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. <i>J Pediatr</i>. 2001;138(1 Suppl):S46-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-drug-information/abstract-text/11148549/pubmed\" target=\"_blank\" id=\"11148549\">11148549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11148550\"></a>Berry GT, Steiner RD. Long-term management of patients with urea cycle disorders. <i>J Pediatr</i>. 2001;138(1 Suppl):S56-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-drug-information/abstract-text/11148550/pubmed\" target=\"_blank\" id=\"11148550\">11148550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bode-Boger SM, Boger RH, Galland A, Tsikas D, Frolich JC. L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. <i>Br J Clin Pharmacol</i>. 1998;46(5):489-497.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-drug-information/abstract-text/9833603/pubmed\" target=\"_blank\" id=\"9833603\">9833603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8794176\"></a>Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. <i>Adv Pediatr</i>. 1996;43:127-170.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-drug-information/abstract-text/8794176/pubmed\" target=\"_blank\" id=\"8794176\">8794176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bushinsky DA, Gennari FJ. Life-threatening hyperkalemia induced by arginine. <i>Ann Intern Med</i>. 1978;89(5, pt 1):632-634.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-drug-information/abstract-text/717931/pubmed\" target=\"_blank\" id=\"717931\">717931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cynober L. Pharmacokinetics of arginine and related amino acids. <i>J Nutr</i>. 2007;137(6 Suppl 2):1646S-1649S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-drug-information/abstract-text/17513441/pubmed\" target=\"_blank\" id=\"17513441\">17513441</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17538087\"></a>Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. <i>N Engl J Med</i>. 2007;356(22):2282-2292.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-drug-information/abstract-text/17538087/pubmed\" target=\"_blank\" id=\"17538087\">17538087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22642880\"></a>H&auml;berle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. <i>Orphanet J Rare Dis</i>. 2012;7:32. doi: 10.1186/1750-1172-7-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-drug-information/abstract-text/22642880/pubmed\" target=\"_blank\" id=\"22642880\">22642880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21290785\"></a>Nagamani SCS, Erez A, Lee B. Argininosuccinate lyase deficiency. In: Adam MP, Ardinger HH, Pagon RA, et al, editors. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2017. Published February 3, 2011. Updated February 2, 2012. <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK51784/\" target=\"_blank\">http://www.ncbi.nlm.nih.gov/books/NBK51784/</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-drug-information/abstract-text/21290785/pubmed\" target=\"_blank\" id=\"21290785\">21290785</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Organization for Rare Disorders. (NORD). The Physician's Guide to Urea Cycle Disorders. Danbury, CT: National Organization for Rare Disorders; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Urea Cycle Disorders Foundation. Available at http://www.nucdf.org/medical_information.htm.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi: 10.1002/phar.1396.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    R-Gene 10 (arginine) [prescribing information]. New York, NY: Pharmacia and Upjohn; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schulman SP, Becker LC, Kass DA, &ldquo;L-Arginine Therapy in Acute Myocardial Infarction. The Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) Randomized Clinical Trial, &ldquo; <i>JAMA</i>, 2006, 295(1):58-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-drug-information/abstract-text/16391217/pubmed\" target=\"_blank\" id=\"16391217\">16391217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tangphao O, Grossmann M, Chalon S, Hoffman BB, Blaschke TF. Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. <i>Br J Clin Pharmacol</i>. 1999;47(3):261-266.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-drug-information/abstract-text/10215749/pubmed\" target=\"_blank\" id=\"10215749\">10215749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Urea Cycle Disorders Conference Group. Consensus statement from a conference for the management of patients with urea cycle disorders. <i>J Pediatr</i>. 2001;138(1 Suppl):S1-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/arginine-drug-information/abstract-text/11148543/pubmed\" target=\"_blank\" id=\"11148543\">11148543</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8883 Version 102.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F136608\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F136622\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F136609\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F136617\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F136610\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F29032178\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F29032179\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F136592\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F136578\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F27747245\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F136594\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F136593\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F45090537\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7905819\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F136585\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F136597\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F136582\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298769\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F136586\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F136600\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F136601\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2572943\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F136581\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F136596\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322999\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038532\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8883|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=arginine-patient-drug-information\" class=\"drug drug_patient\">Arginine: Patient drug information</a></li><li><a href=\"topic.htm?path=arginine-pediatric-drug-information\" class=\"drug drug_pediatric\">Arginine: Pediatric drug information</a></li></ul></div></div>","javascript":null}